within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE07_Fosamprenavir;

model Fosamprenavir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.77,
    Cl = 1.8333333333333333e-05,
    adminDuration = 600,
    adminMass = 1400 / 1000000,
    adminCount = 1,
    Vd = 0.167,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008166666666666666,
    Tlag = 18.0,
    Vdp = 0.206,
    k12 = 1.611111111111111e-05,
    k21 = 1.611111111111111e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Fosamprenavir</td></tr><tr><td>ATC code:</td><td>J05AE07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>167</td><td>L</td></tr>
    <tr><td>clearance:</td><td>66</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Fosamprenavir is a prodrug of amprenavir, a protease inhibitor used as an antiretroviral agent in the treatment of HIV-1 infection. Fosamprenavir is hydrolyzed to amprenavir after oral administration and, when used in combination with other antiretrovirals, reduces viral load and improves immune function. It is approved by health authorities including the FDA, primarily for adults and children over four years old.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects after a single oral dose of 1400 mg fosamprenavir without ritonavir coadministration.</p><h4>References</h4><ol><li><p>Barbour, AM, et al., &amp; Wire, MB (2014). Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. <i>Journal of clinical pharmacology</i> 54(2) 206–214. DOI:<a href=\"https://doi.org/10.1002/jcph.205\">10.1002/jcph.205</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25272370/\">https://pubmed.ncbi.nlm.nih.gov/25272370</a></p></li><li><p>Dolton, MJ, et al., &amp; McLachlan, AJ (2014). Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. <i>Antimicrobial agents and chemotherapy</i> 58(11) 6879–6885. DOI:<a href=\"https://doi.org/10.1128/AAC.03777-14\">10.1128/AAC.03777-14</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25199779/\">https://pubmed.ncbi.nlm.nih.gov/25199779</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AE07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Fosamprenavir;
